成都先导药物开发股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2022 年第一季度报告 证券代码：688222 证券简称：成都先导 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人 JIN LI（李进）、主管会计工作负责人胡春艳及会计机构负责人（会计主管人员）邓 飞明保证季度报告中财务报表信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | | 本报告期比上年 | | --- | --- | --- | --- | | | | | 同期增减变动幅 | | | | | 度(%) | | 营业收入 | | 72,465,855.95 | 4.77 | | 归属于上市公司股东的净利润 | | -7,088,441.60 | -222.60 | | 归属 ...

Financial Performance - The company's operating revenue for Q3 2021 was ¥73,169,078.08, representing an increase of 86.95% compared to the same period last year[5]. - The net profit attributable to shareholders for the same period was ¥9,034,650.49, with a year-to-date increase of 103.24% to ¥29,692,579.59[5]. - Basic earnings per share for Q3 2021 was ¥0.02, with a year-to-date increase of 75.00% to ¥0.07[6]. - In the first nine months of 2021, the company achieved operating revenue of RMB 227.31 million, representing a year-on-year growth of 80.50%[16]. - The net profit attributable to shareholders increased by 103.24% year-on-year, with a net profit excluding non-recurring gains and losses rising by 15,632.33%[16]. - The total comprehensive income for the third quarter of 2021 was CNY 25,718,921.05, compared to CNY 15,287,160.29 in the same period of 2020, representing a year-over-year increase of approximately 68.5%[27]. - Basic earnings per share increased to CNY 0.07 from CNY 0.04, reflecting a 75% growth in profitability[27]. Research and Development - Total R&D investment for Q3 2021 was ¥17,661,537.97, a decrease of 37.73% compared to the same period last year[6]. - R&D investment as a percentage of operating revenue decreased by 48.33 percentage points to 24.14% in Q3 2021[6]. - The company has established multiple deep collaborations in drug research and development with various biotech firms, including UPPTHERA and BioAge[17]. - A new molecular structure co-developed with FORMA received registration certification from the American Chemical Society[17]. - The company is advancing its research on artificial intelligence applications in drug discovery, collaborating with Tencent AI Lab on a molecular skeleton transition algorithm[17]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥1,673,795,519.04, reflecting a 1.56% increase from the end of the previous year[6]. - Total liabilities increased to ¥387,574,169.88 in the third quarter of 2021, compared to ¥370,075,489.20 in the same period of 2020, marking an increase of about 4.0%[24]. - The company's total assets as of the end of the third quarter of 2021 amounted to ¥1,673,795,519.04, up from ¥1,648,005,753.49 at the end of 2020[25]. - The total equity attributable to shareholders reached ¥1,286,221,349.16, compared to ¥1,277,930,264.29 in the previous year, reflecting a growth of about 0.6%[24]. - The company’s contract assets increased significantly to ¥19,281,743.68 from ¥3,936,460.48, indicating a growth of approximately 389.5%[23]. Cash Flow - Cash flow from operating activities for the year-to-date period was ¥25,186,166.57, indicating an increase due to higher sales receipts[10]. - The company reported a net cash flow from operating activities growth of 162.99% compared to the previous year[16]. - Cash inflows from operating activities for the first three quarters of 2021 amounted to CNY 246,506,997.61, up from CNY 124,316,725.58 in the same period of 2020, indicating a 98.5% increase[29]. - The net cash flow from operating activities for the third quarter was CNY 25,186,166.57, a significant recovery from a negative cash flow of CNY -39,985,974.19 in the previous year[29]. - Cash inflows from investment activities totaled CNY 1,635,409,651.67, compared to CNY 936,525,126.13 in the same period of 2020, marking a 74.5% increase[30]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 10,345[12]. - Major shareholders included JIN LI with 20.43% ownership and 拉萨经济技术开发区华博医疗器械有限公司 with 14.08% ownership[12]. Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[27].

Financial Performance - The company reported a significant increase in revenue for the first half of 2021, with total revenue reaching RMB 500 million, representing a 25% year-over-year growth[1]. - Revenue for the first half of 2021 reached $500 million, representing a 15% increase year-over-year[14]. - The company achieved revenue of 154.14 million yuan, a year-on-year increase of 77.60%, with domestic customer revenue reaching 22.66 million yuan, up 1,362%, accounting for 14.70% of total revenue[101]. - The net profit attributable to shareholders for the first half of 2021 was approximately ¥20.66 million, up 33.88% from ¥15.43 million in the previous year[24]. - The net profit after deducting non-recurring gains and losses was approximately ¥11.73 million, reflecting a 26.51% increase from ¥9.27 million in the previous year[24]. - The company's operating revenue for the first half of 2021 was approximately ¥154.14 million, representing a 77.60% increase compared to ¥86.79 million in the same period last year[23]. - The company reported a significant increase in user data, with a 25% growth in active users compared to the previous year[13]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in the first half of 2021, representing a year-over-year growth of 25%[169]. User Growth - User data showed an increase in active users, with the total number of users growing to 1.2 million, up 30% compared to the same period last year[1]. - User data showed a growth in active users, reaching 10 million, which is a 15% increase compared to the previous period[169]. Future Outlook - The company provided a positive outlook for the second half of 2021, projecting a revenue growth of 20% to 30% based on current market trends and product demand[1]. - Future guidance indicates an expected revenue growth of 20% for the next fiscal year, driven by new product launches and market expansion[14]. - The company provided a positive outlook for the next quarter, projecting revenue growth of B% and an expected increase in user engagement metrics[160]. - The company plans to invest $50 million in R&D for the development of novel drug candidates over the next year[14]. - New product launches are expected to contribute an additional 300 million in revenue by the end of the year[169]. Market Expansion - The company is expanding its market presence, targeting international markets with a focus on North America and Europe, aiming for a 15% increase in market share by the end of 2022[1]. - The company is expanding its market presence in Asia, targeting a 30% increase in market share within the next two years[14]. - Market expansion strategies include entering E new geographical markets, which are expected to contribute an additional F million in revenue[158]. - The company has plans to enter three new international markets by Q4 2021, aiming for a 10% market share in each[169]. Research and Development - New product development efforts have led to the successful launch of three new drug candidates, which are expected to enter clinical trials by Q4 2021[1]. - The company is investing in new technologies, with a budget of RMB 100 million dedicated to R&D for innovative drug delivery systems[1]. - The company has initiated the development of new mRNA-based therapeutics, aiming to enter clinical trials by Q4 2022[14]. - The company plans to invest heavily in R&D, with a budget allocation of 200 million for new technologies and product development[169]. - The company has approximately 20 internal new drug projects, with 4 projects having received clinical trial approval and currently in different stages of clinical and preclinical trials[32]. Acquisitions and Partnerships - Strategic acquisitions are being considered to enhance the company's research capabilities, with a budget of RMB 200 million allocated for potential mergers and acquisitions in 2021[1]. - A strategic acquisition of a biotech firm was completed, enhancing the company's capabilities in drug discovery and development[14]. - The acquisition of Vernalis (R&D) has positioned the company as a leader in FBDD/SBDD technology, with over 20 years of experience in drug discovery[48]. - The company has established partnerships with leading research institutions to bolster its drug development pipeline, aiming to accelerate time-to-market for new therapies[1]. Risk Management - The management highlighted the importance of risk management strategies in navigating potential market fluctuations and regulatory changes[1]. - The company faces risks related to technology substitution in drug screening methods and the potential for new drug development failures due to the innovative nature of its projects[110]. - The company faces risks related to high customer concentration, which could adversely affect business operations and financial conditions if major clients experience difficulties[112]. Compliance and Governance - The board of directors emphasized the commitment to maintaining transparency and accuracy in financial reporting, ensuring compliance with regulatory standards[1]. - The company has committed to maintaining transparency and accountability in its operations, adhering to all relevant regulations[169]. - The company has not reported any significant violations or penalties against the company or its executives during the period[169]. Environmental Responsibility - The company has established a comprehensive environmental protection system to ensure compliance with regulations during its operations[136]. - The company implemented energy-saving measures, including regulating air conditioning temperatures to reduce electricity consumption[139]. - The company committed to using eco-friendly materials and promoting the use of reusable materials and packaging[139].

Financial Performance - Operating revenue rose by 56.79% to CNY 69,164,316.00 year-on-year[5] - Net profit attributable to shareholders decreased by 33.85% to CNY 5,781,934.11 compared to the same period last year[5] - Basic earnings per share dropped by 50.00% to CNY 0.01 compared to the previous year[5] - Net profit increased by 61.99% to CNY 5,781,934.11 compared to the same period last year, despite the negative impact from the integration of two new UK subsidiaries[15] - Comprehensive income for Q1 2021 totaled CNY 11,129,768.46, compared to CNY 8,364,450.33 in Q1 2020, reflecting an increase of 32.9%[25] - Net profit for Q1 2021 was CNY 5,781,934.11, a decrease of 33.5% from CNY 8,740,267.66 in Q1 2020[25] Cash Flow - The net cash flow from operating activities was CNY 14,094,598.87, a significant improvement from a negative cash flow of CNY -1,897,162.63 in the previous year[5] - Cash flow from operating activities reached CNY 14,094,598.87, a significant improvement from a negative cash flow of CNY -1,897,162.63 in Q1 2020[15] - Cash flow from financing activities improved to CNY -745,785.04 from CNY -5,224,241.78 in Q1 2020, reflecting reduced IPO-related payments[15] Assets and Liabilities - Total assets increased by 2.89% to CNY 1,695,639,358.72 compared to the end of the previous year[5] - The total assets as of March 31, 2021, amounted to CNY 1,695,639,358.72, up from CNY 1,648,005,753.49 at the end of 2020[18] - The total liabilities increased to CNY 407,695,135.23 from CNY 370,075,489.20 at the end of 2020[18] - The company's deferred tax assets decreased by 61.59% to RMB 1,414,997.46, mainly due to profits in Q1 2021 offsetting previously recognized losses[13] - The accounts payable increased by 56.06% to RMB 14,609,507.20, primarily due to increased technical service fees owed by Vernalis[13] Shareholder Information - The total number of shareholders at the end of the reporting period was 7,696[10] - The top shareholder, JIN LI, holds 20.43% of the shares, totaling 81,876,948 shares[11] Research and Development - R&D investment as a percentage of operating revenue decreased by 30.09 percentage points to 20.63%[5] - Research and development expenses decreased by 36.22% to RMB 14,270,243.49, reflecting a shift in focus away from self-developed projects[14] - Research and development expenses for Q1 2021 were CNY 14,270,243.49, down 36.3% from CNY 22,375,778.77 in Q1 2020[24] Operating Costs - Operating costs surged to RMB 35,783,045.16, a 322.85% increase from RMB 8,462,383.89 in the previous year, attributed to a shift towards commercial projects and lower gross margins from Vernalis[14] - Total operating costs for Q1 2021 were CNY 68,611,515.30, up 96.7% from CNY 34,858,761.09 in Q1 2020[24] Other Income and Expenses - Non-recurring gains and losses totaled CNY 2,928,158.85 for the period[9] - The company recognized other income of RMB 3,054,359.81, an 85.87% increase, mainly due to government subsidies received by Vernalis during the reporting period[14] - The financial expenses for Q1 2021 showed a notable increase in interest expenses, which reached RMB 896,516.99, a 506.13% rise compared to RMB 147,907.32 in the previous year[14] Equity - The company's equity attributable to shareholders rose to CNY 1,287,944,223.49, compared to CNY 1,277,930,264.29 at the end of 2020[18]

2020 年年度报告 公司代码：688222 公司简称：成都先导 成都先导药物开发股份有限公司 2020 年年度报告 1 / 223 2020 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司已经在本报告中阐述了可能存在的风险，请参阅第四节"经营情况讨论与分析"等有关章节 中关于公司可能面临的风险因素以及对策部分的内容。敬请投资者注意投资风险，审慎作出投资 决定。 三、 公司全体董事出席董事会会议。 四、 德勤华永会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报 告。 五、 公司负责人 JIN LI、主管会计工作负责人胡春艳 及会计机构负责人（会计主管人员）邓飞 明声明：保证年度报告中财务报告的真实、准确、完整。 六、 经董事会审议的报告期利润分配预案或公积金转增股本预案 公司拟以实施2020年度分红派息股权登记日的总股本为基数，向全体股东每10股派发现金红 利0.5元（含税）。截至2020年12月31日，公司总股本为400,680,000 ...

Financial Performance - Operating revenue decreased by 19.06% to CNY 125,929,094.01 for the first nine months compared to the same period last year[6]. - Net profit attributable to shareholders decreased by 80.34% to CNY 14,609,816.84 for the first nine months compared to the same period last year[6]. - The weighted average return on net assets decreased by 15.82 percentage points to 1.59%[6]. - Basic earnings per share decreased by 80.95% to CNY 0.04[7]. - Other income fell by 69.39% to RMB 14,725,962.60, as there were no significant government grants in 2020 compared to the previous year[17]. - The net profit attributable to shareholders for the first three quarters of 2020 was RMB 14,609,816.84, a decrease of 80.34% compared to RMB 74,309,852.71 in the same period of 2019[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 82,255.94, down 99.75% from RMB 33,471,642.35 in the previous year[18]. - The company's operating revenue for the first three quarters of 2020 was RMB 125,929,100, a year-on-year decrease of 19.06% due to the impact of the global pandemic[18]. - The net profit for Q3 2020 was ¥2,305,880.94, compared to a net profit of ¥20,024,870.72 in Q3 2019, indicating a significant decline[35]. - The total profit for Q3 2020 was reported at -¥2,742,232.92, contrasting with a profit of ¥20,967,450.38 in Q3 2019[35]. Assets and Liabilities - Total assets increased by 106.07% to CNY 1,309,248,582.95 compared to the end of the previous year[6]. - Total liabilities decreased to RMB 83,397,570.68 from RMB 123,581,043.87 in the previous year[24]. - The total equity attributable to shareholders increased to RMB 1,225,851,012.27 from RMB 511,772,243.86 at the end of 2019[24]. - Total assets as of September 30, 2020, reached CNY 1,345,270,024.87, a significant increase from CNY 661,373,096.91 as of December 31, 2019[27]. - Total liabilities decreased to CNY 69,191,037.64 from CNY 109,804,355.96, indicating improved financial stability[28]. - The company's equity increased to CNY 1,276,078,987.23 from CNY 551,568,740.95, reflecting a strong capital position[28]. Cash Flow - The company reported a net cash flow from operating activities of CNY -39,985,974.19 for the first nine months, a decrease of 127.77% compared to the same period last year[6]. - Cash flow from operating activities for the first three quarters of 2020 was CNY 124,316,725.58, down 55.6% from CNY 279,979,552.98 in the same period of 2019[39]. - Net cash flow from operating activities was negative at CNY -39,985,974.19, contrasting with a positive CNY 143,996,728.00 in the prior year[39]. - Cash inflow from investment activities totaled CNY 936,525,126.13, a substantial increase from CNY 505,561,822.64 in the previous year[39]. - Cash outflow for investment activities was CNY 1,403,497,527.91, compared to CNY 575,917,339.50 in the same period last year[40]. - Net cash flow from investment activities was negative at CNY -466,972,401.78, worsening from CNY -70,355,516.86 in 2019[40]. - Cash flow from financing activities generated CNY 766,971,607.68, with a net cash flow of CNY 696,631,154.92 after outflows[40]. Research and Development - R&D expenses accounted for 59.46% of operating revenue, an increase of 21.9 percentage points compared to the previous year[7]. - Research and development expenses increased by 28.11% to RMB 74,873,400 in the first three quarters of 2020[18]. - R&D expenses for the first three quarters of 2020 totaled CNY 74,873,434.98, up 28.4% from CNY 58,443,094.96 in the same period of 2019[30]. - Research and development expenses increased to ¥26,272,231.73 in Q3 2020, up from ¥18,710,133.90 in Q3 2019, reflecting a 40% increase[35]. Shareholder Information - The total number of shareholders reached 7,763 by the end of the reporting period[12]. - The largest shareholder, LI.JIN, holds 20.43% of the shares, totaling 81,876,948 shares[12]. Inventory and Prepayments - Prepayments surged by 410.58% to RMB 14,457,675.81, primarily due to increased advance payments for materials and outsourced services[16]. - Inventory rose by 78.83% to RMB 23,413,236.77, attributed to higher raw material purchases[16]. - Inventory levels rose to CNY 23,413,236.77 from CNY 13,092,557.77, indicating increased production or stockpiling[26]. Compliance and Accounting Standards - The company implemented new revenue and leasing standards starting January 1, 2020, affecting the financial statements[47]. - The company is focused on adjusting financial reporting in compliance with new accounting standards, enhancing transparency and accuracy[47]. - The company adopted new revenue recognition standards starting January 1, 2020, impacting financial reporting[52]. - The company is committed to compliance with updated accounting standards as of 2020[52].

2020 年半年度报告 公司代码：688222 公司简称：成都先导 成都先导药物开发股份有限公司 2020 年半年度报告 1 / 167 2020 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司已经在本报告中阐述了可能存在的风险，请参阅第四节"经营情况讨论与分析"等有关 章节中关于公司可能面临的风险因素以及对策部分的内容。敬请投资者注意投资风险，审慎作出 投资决定。 三、 公司全体董事出席董事会会议。 无 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告存在一些基于对未来政策和经济走势的主观假设和判断而做出的预见性陈述，受诸多 可变因素影响，实际结果或趋势可能会与这些预见性陈述出现差异。 本报告所涉及的公司未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质承诺， 敬请投资者注意投资风险。 九、 是否存在被控股股东及其关联方非经营性占用资金情况 否 十、 是否存在违反规定决策程序对外 ...

2020 年第一季度报告 二、 公司基本情况 2.1 主要财务数据 | | | | 单位：元 币种：人民币 | | | | --- | --- | --- | --- | --- | --- | | | 本报告期末 | 上年度末 | 本报告期末比上年度末增 | | | | | | | 减(%) | | | | 总资产 | 634,167,874.02 | 635,353,287.73 | -0.19% | | | | 归属于上市公司 | 521,091,841.51 | 511,772,243.86 | | | 1.82% | | 股东的净资产 | | | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减(%) | | | | 经营活动产生的 | -1,897,162.63 | 44,898,574.81 | | | -104.23% | | 现金流量净额 | | | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减（%） | | | | 营业收入 | 44,112,298.63 | 50,753,027.36 | | | -13.08% | | ...